Evaxion Biotech A/S (NASDAQ:EVAX) Earns “Buy” Rating from HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $14.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 471.43% from the company’s current price.

Evaxion Biotech A/S Stock Performance

EVAX opened at $2.45 on Monday. The company has a market capitalization of $2.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.28. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 1-year low of $2.31 and a 1-year high of $27.50. The business has a 50 day moving average price of $4.99 and a two-hundred day moving average price of $10.74.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Thursday, October 31st. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.40. The firm had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. Research analysts predict that Evaxion Biotech A/S will post -0.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission (SEC). 11.04% of the stock is owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.